Fractionated Carbon Dioxide Laser for the Treatment of Vulvar Lichen Sclerosus : A Randomized Controlled Trial
Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved..
OBJECTIVE: To estimate the efficacy of fractionated carbon dioxide (CO2) laser therapy for vulvar lichen sclerosus.
METHODS: We conducted a prospective, double-blind, randomized, sham-controlled, trial conducted in a clinic specializing in vulvar disorders. The study participants were 40 women with active vulvar lichen sclerosus confirmed with biopsy who were abstaining from topical and systemic treatments for at least 4 weeks before enrollment. Women were randomized in a 1:1 ratio to receive either five sham laser treatments or five fractionated CO2 treatments in a 24-week period. Study participants, treating clinicians, and the evaluating pathologist were blinded. The primary endpoint was the change in the histopathology scale score between pretreatment and posttreatment biopsies. We estimated 20 per group for 80% power to detect a 40% reduction in the histopathology scale score with up to 10% attrition. A secondary endpoint was the change in the validated CSS (Clinical Scoring System for Vulvar Lichen Sclerosus).
RESULTS: From November 2018 to June 2020, 40 women were randomized to participate in the trial, and 37 women (19 fractionated CO2, 18 sham) were included in an intention-to-treat (ITT) analysis. Three women were excluded from the ITT analysis because they did not have posttreatment biopsies and, therefore, a posttreatment histopathology scale score could not be obtained. There was a 0.20 reduction (improvement) in histopathology scale score from baseline in the active treatment group (95% CI -1.1, 0.80, P=.74) and a 0.1 increase from baseline in the sham treatment group (95% CI -0.90, 1.0, P=.91). The change in histopathology scale score between the active and sham arm was not statistically significant (95% CI -1.14, 1.06, P=.76).
CONCLUSION: Fractionated CO2 is not an effective monotherapy treatment for vulvar lichen sclerosus.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03665584.
FUNDING SOURCE: Additional funding for this study was supplied by El.En Group, Florence, Italy, the manufacturer of the laser used in this study. In addition, El.En Group supplied the laser used in the study.
Errataetall: |
CommentIn: Obstet Gynecol. 2021 Jun 1;137(6):965-967. - PMID 33957659 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:137 |
---|---|
Enthalten in: |
Obstetrics and gynecology - 137(2021), 6 vom: 01. Juni, Seite 979-987 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mitchell, Leia [VerfasserIn] |
---|
Links: |
---|
Themen: |
Journal Article |
---|
Anmerkungen: |
Date Completed 26.07.2021 Date Revised 06.07.2023 published: Print ClinicalTrials.gov: NCT03665584 CommentIn: Obstet Gynecol. 2021 Jun 1;137(6):965-967. - PMID 33957659 Citation Status MEDLINE |
---|
doi: |
10.1097/AOG.0000000000004409 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM325095221 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM325095221 | ||
003 | DE-627 | ||
005 | 20231225191717.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/AOG.0000000000004409 |2 doi | |
028 | 5 | 2 | |a pubmed24n1083.xml |
035 | |a (DE-627)NLM325095221 | ||
035 | |a (NLM)33957648 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mitchell, Leia |e verfasserin |4 aut | |
245 | 1 | 0 | |a Fractionated Carbon Dioxide Laser for the Treatment of Vulvar Lichen Sclerosus |b A Randomized Controlled Trial |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.07.2021 | ||
500 | |a Date Revised 06.07.2023 | ||
500 | |a published: Print | ||
500 | |a ClinicalTrials.gov: NCT03665584 | ||
500 | |a CommentIn: Obstet Gynecol. 2021 Jun 1;137(6):965-967. - PMID 33957659 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved. | ||
520 | |a OBJECTIVE: To estimate the efficacy of fractionated carbon dioxide (CO2) laser therapy for vulvar lichen sclerosus | ||
520 | |a METHODS: We conducted a prospective, double-blind, randomized, sham-controlled, trial conducted in a clinic specializing in vulvar disorders. The study participants were 40 women with active vulvar lichen sclerosus confirmed with biopsy who were abstaining from topical and systemic treatments for at least 4 weeks before enrollment. Women were randomized in a 1:1 ratio to receive either five sham laser treatments or five fractionated CO2 treatments in a 24-week period. Study participants, treating clinicians, and the evaluating pathologist were blinded. The primary endpoint was the change in the histopathology scale score between pretreatment and posttreatment biopsies. We estimated 20 per group for 80% power to detect a 40% reduction in the histopathology scale score with up to 10% attrition. A secondary endpoint was the change in the validated CSS (Clinical Scoring System for Vulvar Lichen Sclerosus) | ||
520 | |a RESULTS: From November 2018 to June 2020, 40 women were randomized to participate in the trial, and 37 women (19 fractionated CO2, 18 sham) were included in an intention-to-treat (ITT) analysis. Three women were excluded from the ITT analysis because they did not have posttreatment biopsies and, therefore, a posttreatment histopathology scale score could not be obtained. There was a 0.20 reduction (improvement) in histopathology scale score from baseline in the active treatment group (95% CI -1.1, 0.80, P=.74) and a 0.1 increase from baseline in the sham treatment group (95% CI -0.90, 1.0, P=.91). The change in histopathology scale score between the active and sham arm was not statistically significant (95% CI -1.14, 1.06, P=.76) | ||
520 | |a CONCLUSION: Fractionated CO2 is not an effective monotherapy treatment for vulvar lichen sclerosus | ||
520 | |a CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT03665584 | ||
520 | |a FUNDING SOURCE: Additional funding for this study was supplied by El.En Group, Florence, Italy, the manufacturer of the laser used in this study. In addition, El.En Group supplied the laser used in the study | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
700 | 1 | |a Goldstein, Andrew T |e verfasserin |4 aut | |
700 | 1 | |a Heller, Debra |e verfasserin |4 aut | |
700 | 1 | |a Mautz, Theodora |e verfasserin |4 aut | |
700 | 1 | |a Thorne, Chelsea |e verfasserin |4 aut | |
700 | 1 | |a Joyce Kong, So Yeon |e verfasserin |4 aut | |
700 | 1 | |a Sophocles, Maria E |e verfasserin |4 aut | |
700 | 1 | |a Tolson, Hillary |e verfasserin |4 aut | |
700 | 1 | |a Krapf, Jill M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Obstetrics and gynecology |d 1953 |g 137(2021), 6 vom: 01. Juni, Seite 979-987 |w (DE-627)NLM000021555 |x 1873-233X |7 nnns |
773 | 1 | 8 | |g volume:137 |g year:2021 |g number:6 |g day:01 |g month:06 |g pages:979-987 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/AOG.0000000000004409 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 137 |j 2021 |e 6 |b 01 |c 06 |h 979-987 |